Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET
Company Participants
Christine Lindenboom - Chief Corporate Communications Officer
Yvonne Greenstreet - Chief Executive Officer
Tolga Tanguler - Chief Commercial Officer
Pushkal Garg - Chief Medical Officer
Jeff Poulton - Chief Financial Officer
Conference Call Participants
Ellie Merle - UBS
Gena Wang - Barclays
David Lebowitz - Citi
Paul Matteis - Stifel
Ritu Baral - TD Cowen
Jessica Fye - JPMorgan
Gary Nachman - Raymond James
Kostas Biliouris - BMO Capital
Tazeen Ahmad - Bank of America
Operator
Good day, everyone, and welcome to today's Alnylam Pharmaceuticals Q3 2024 Earnings Conference Call. At this time, all participants are in a listen-only-mode. Later, you will have the opportunity to ask questions during the question-and-answer session. [Operator Instructions] Please note this call is being recorded, and I will be standing by if you should need any assistance.
It is now my pleasure to turn the conference over to the company.
Christine Lindenboom
Good morning. I'm Christine Lindenboom, Chief Corporate Communications Officer at Alnylam. With me today are Yvonne Greenstreet, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Pushkal Garg, Chief Medical Officer; and Jeff Poulton, Chief Financial Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, investors.alnylam.com/events.
During today's call, as outlined in Slide 2, Yvonne will offer introductory remarks and provide some general context. Tolga will provide an update on our global commercial progress. Pushkal will review pipeline updates and clinical progress, and Jeff will review financials and guidance, followed by a summary of upcoming milestones before we open the call for your questions.
I would like to remind you that this call will contain remarks concerning Alnylam's future expectations, plans and prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent periodic report on file with the SEC. In addition, any forward-looking statements represent our views only as of the date of this recording and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements.